Study identifier:D6830C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:2024-514213-35-00
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
asthma
Phase 1/2
No
AZD8630
All
24
Interventional
18 Years - 80 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD8630 Dose A Participants will self-administer AZD8630 Dose A daily from Day 1 up to Day 14. | Drug: AZD8630 AZD8630 will be administered via dry powder inhalation (DPI). Device: Saphira device AZD8630 or placebo will be administered to participants via Saphira device. |
Placebo Comparator: Placebo Participants will self-administer corresponding placebo daily from Day 1 up to Day 14. | Other: Placebo Placebo will be administered via DPI. Device: Saphira device AZD8630 or placebo will be administered to participants via Saphira device. |